Back to Search Start Over

1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.

Authors :
Lai MJ
Ojha R
Lin MH
Liu YM
Lee HY
Lin TE
Hsu KC
Chang CY
Chen MC
Nepali K
Chang JY
Liou JP
Source :
European journal of medicinal chemistry [Eur J Med Chem] 2019 Jan 15; Vol. 162, pp. 612-630. Date of Electronic Publication: 2018 Nov 03.
Publication Year :
2019

Abstract

We report structure-activity relationships of 1-arylsulfonyl indoline based benzamides. The benzamide (9) exhibits striking tubulin inhibition with an IC <subscript>50</subscript> value of 1.1 μM, better than that of combretastain A-4 (3), and substantial antiproliferative activity against a variety of cancer cells, including MDR-positive cell lines with an IC <subscript>50</subscript> value of 49 nM (KB), 79 nM (A549), 63 nM (MKN45), 64 nM (KB-VIN10), 43 nM (KB-S15), and 46 nM (KB-7D). Dual inhibitory potential of compound 9 was found as it demonstrated significant inhibitory potential against HDAC1, 2 and 6 in comparison to MS-275 (6). Some key interactions of 9 with the amino acid residues of the active site of tubulin and with amino acid residues of HDAC 1 isoform have been figured out by molecular modeling. Compound 9 also demonstrated significant in vivo efficacy in the human non-small cell lung cancer A549 xenograft model as well as B-cell lymphoma BJAB xenograft tumor model.<br /> (Copyright © 2018. Published by Elsevier Masson SAS.)

Details

Language :
English
ISSN :
1768-3254
Volume :
162
Database :
MEDLINE
Journal :
European journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
30476825
Full Text :
https://doi.org/10.1016/j.ejmech.2018.10.066